#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Multilocus	_
1-2	11-18	genetic	_
1-3	19-26	profile	_
1-4	27-29	in	_
1-5	30-42	dopaminergic	_
1-6	43-50	pathway	_
1-7	51-60	modulates	_
1-8	61-64	the	_
1-9	65-73	striatum	_
1-10	74-77	and	_
1-11	78-85	working	_
1-12	86-92	memory	_
1-13	93-101	Dopamine	_
1-14	102-104	is	_
1-15	105-113	critical	_
1-16	114-116	in	_
1-17	117-132	pathophysiology	_
1-18	133-136	and	_
1-19	137-144	therapy	_
1-20	145-147	of	_
1-21	148-161	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-22	162-163	.	_

2-1	164-168	Many	_
2-2	169-176	studies	_
2-3	177-181	have	_
2-4	182-190	reported	_
2-5	191-198	altered	_
2-6	199-211	dopaminergic	_
2-7	212-220	activity	_
2-8	221-223	in	_
2-9	224-227	the	_
2-10	228-234	dorsal	_
2-11	235-238	but	_
2-12	239-242	not	_
2-13	243-250	ventral	_
2-14	251-259	striatum	_
2-15	260-262	in	_
2-16	263-276	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-17	277-278	.	_

3-1	279-284	Based	_
3-2	285-287	on	_
3-3	288-291	the	_
3-4	292-299	largest	_
3-5	300-311	genome-wide	_
3-6	312-323	association	_
3-7	324-329	study	_
3-8	330-332	of	_
3-9	333-346	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-10	347-349	to	_
3-11	350-354	date	_
3-12	355-356	,	_
3-13	357-359	we	_
3-14	360-370	calculated	_
3-15	371-374	the	_
3-16	375-384	polygenic	_
3-17	385-389	risk	_
3-18	390-395	score	_
3-19	396-397	(	_
3-20	398-402	PGRS	_
3-21	403-404	)	_
3-22	405-407	of	_
3-23	408-412	each	_
3-24	413-420	subject	_
3-25	421-423	in	_
3-26	424-425	a	_
3-27	426-433	healthy	_
3-28	434-441	general	_
3-29	442-447	group	_
3-30	448-449	,	_
3-31	450-459	including	_
3-32	460-463	all	_
3-33	464-474	variations	_
3-34	475-477	in	_
3-35	478-481	the	_
3-36	482-485	set	_
3-37	486-488	of	_
3-38	489-501	functionally	_
3-39	502-509	related	_
3-40	510-515	genes	_
3-41	516-524	involved	_
3-42	525-527	in	_
3-43	528-536	dopamine	_
3-44	537-553	neurotransmitter	_
3-45	554-560	system	_
3-46	561-562	.	_

4-1	563-565	We	_
4-2	566-571	aimed	_
4-3	572-574	to	_
4-4	575-579	test	_
4-5	580-587	whether	_
4-6	588-591	the	_
4-7	592-599	genetic	_
4-8	600-610	variations	_
4-9	611-613	in	_
4-10	614-617	the	_
4-11	618-630	dopaminergic	_
4-12	631-638	pathway	_
4-13	639-643	that	_
4-14	644-648	have	_
4-15	649-653	been	_
4-16	654-664	identified	_
4-17	665-667	as	_
4-18	668-678	associated	_
4-19	679-683	with	_
4-20	684-697	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-21	698-701	are	_
4-22	702-709	related	_
4-23	710-712	to	_
4-24	713-716	the	_
4-25	717-725	function	_
4-26	726-728	of	_
4-27	729-732	the	_
4-28	733-741	striatum	_
4-29	742-745	and	_
4-30	746-748	to	_
4-31	749-756	working	_
4-32	757-763	memory	_
4-33	764-765	.	_

5-1	766-768	We	_
5-2	769-774	found	_
5-3	775-779	that	_
5-4	780-781	a	_
5-5	782-788	higher	_
5-6	789-793	PGRS	_
5-7	794-797	was	_
5-8	798-811	significantly	_
5-9	812-822	associated	_
5-10	823-827	with	_
5-11	828-838	impairment	_
5-12	839-841	in	_
5-13	842-849	working	_
5-14	850-856	memory	_
5-15	857-858	.	_

6-1	859-867	Moreover	_
6-2	868-869	,	_
6-3	870-883	resting-state	_
6-4	884-894	functional	_
6-5	895-907	connectivity	_
6-6	908-916	analysis	_
6-7	917-925	revealed	_
6-8	926-930	that	_
6-9	931-933	as	_
6-10	934-937	the	_
6-11	938-947	polygenic	_
6-12	948-952	risk	_
6-13	953-958	score	_
6-14	959-968	increased	_
6-15	969-970	,	_
6-16	971-974	the	_
6-17	975-986	connections	_
6-18	987-994	between	_
6-19	995-999	left	_
6-20	1000-1007	putamen	_
6-21	1008-1011	and	_
6-22	1012-1019	caudate	_
6-23	1020-1023	and	_
6-24	1024-1027	the	_
6-25	1028-1035	default	_
6-26	1036-1040	mode	_
6-27	1041-1048	network	_
6-28	1049-1053	grew	_
6-29	1054-1062	stronger	_
6-30	1063-1064	,	_
6-31	1065-1070	while	_
6-32	1071-1074	the	_
6-33	1075-1086	connections	_
6-34	1087-1091	with	_
6-35	1092-1095	the	_
6-36	1096-1111	fronto-parietal	_
6-37	1112-1119	network	_
6-38	1120-1124	grew	_
6-39	1125-1131	weaker	_
6-40	1132-1133	.	_

7-1	1134-1137	Our	_
7-2	1138-1146	findings	_
7-3	1147-1150	may	_
7-4	1151-1155	shed	_
7-5	1156-1161	light	_
7-6	1162-1164	on	_
7-7	1165-1168	the	_
7-8	1169-1179	biological	_
7-9	1180-1189	mechanism	_
7-10	1190-1200	underlying	_
7-11	1201-1204	the	_
7-12	1205-1206	“	_
7-13	1207-1215	dopamine	_
7-14	1216-1226	hypothesis	_
7-15	1227-1228	”	_
7-16	1229-1231	of	_
7-17	1232-1245	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-18	1246-1249	and	_
7-19	1250-1257	provide	_
7-20	1258-1262	some	_
7-21	1263-1275	implications	_
7-22	1276-1285	regarding	_
7-23	1286-1289	the	_
7-24	1290-1299	polygenic	_
7-25	1300-1307	effects	_
7-26	1308-1310	on	_
7-27	1311-1314	the	_
7-28	1315-1327	dopaminergic	_
7-29	1328-1336	activity	_
7-30	1337-1339	in	_
7-31	1340-1343	the	_
7-32	1344-1348	risk	_
7-33	1349-1352	for	_
7-34	1353-1366	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-35	1367-1368	.	_

8-1	1369-1378	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-2	1379-1382	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-3	1383-1390	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-4	1391-1399	Subjects	_
8-5	1400-1405	Three	_
8-6	1406-1413	hundred	_
8-7	1414-1426	twenty-three	_
8-8	1427-1434	healthy	_
8-9	1435-1440	young	_
8-10	1441-1448	Chinese	_
8-11	1449-1457	subjects	_
8-12	1458-1459	(	_
8-13	1460-1464	mean	_
8-14	1465-1468	age	_
8-15	1469-1470	:	_
8-16	1471-1475	22.7	_
8-17	1476-1477	±	_
8-18	1478-1481	2.5	_
8-19	1482-1487	years	_
8-20	1488-1489	;	_
8-21	1490-1493	age	_
8-22	1494-1499	range	_
8-23	1500-1501	=	_
8-24	1502-1507	18–31	_
8-25	1508-1513	years	_
8-26	1514-1515	;	_
8-27	1516-1519	157	_
8-28	1520-1525	males	_
8-29	1526-1527	)	_
8-30	1528-1532	were	_
8-31	1533-1542	recruited	_
8-32	1543-1544	.	_

9-1	1545-1548	The	_
9-2	1549-1558	exclusion	_
9-3	1559-1567	criteria	_
9-4	1568-1572	were	_
9-5	1573-1582	identical	_
9-6	1583-1585	to	_
9-7	1586-1589	our	_
9-8	1590-1598	previous	_
9-9	1599-1604	study	_
9-10	1605-1609	that	_
9-11	1610-1614	used	_
9-12	1615-1618	the	_
9-13	1619-1623	same	_
9-14	1624-1632	database	_
9-15	1633-1634	.	_

10-1	1635-1637	We	_
10-2	1638-1647	carefully	_
10-3	1648-1653	asked	_
10-4	1654-1662	subjects	_
10-5	1663-1665	to	_
10-6	1666-1672	ensure	_
10-7	1673-1677	that	_
10-8	1678-1681	had	_
10-9	1682-1684	no	_
10-10	1685-1693	personal	_
10-11	1694-1696	or	_
10-12	1697-1703	family	_
10-13	1704-1711	history	_
10-14	1712-1714	of	_
10-15	1715-1727	neurological	_
10-16	1728-1730	or	_
10-17	1731-1742	psychiatric	_
10-18	1743-1750	disease	_
10-19	1751-1752	,	_
10-20	1753-1757	head	_
10-21	1758-1764	injury	_
10-22	1765-1766	,	_
10-23	1767-1778	psychiatric	_
10-24	1779-1788	treatment	_
10-25	1789-1790	,	_
10-26	1791-1795	drug	_
10-27	1796-1798	or	_
10-28	1799-1806	alcohol	_
10-29	1807-1812	abuse	_
10-30	1813-1814	,	_
10-31	1815-1829	hypothyroidism	_
10-32	1830-1832	or	_
10-33	1833-1838	other	_
10-34	1839-1845	mental	_
10-35	1846-1854	diseases	_
10-36	1855-1858	and	_
10-37	1859-1861	no	_
10-38	1862-1879	contraindications	_
10-39	1880-1882	to	_
10-40	1883-1891	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
10-41	1892-1901	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
10-42	1902-1909	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
10-43	1910-1911	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
10-44	1912-1915	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
10-45	1916-1917	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
10-46	1918-1927	screening	_
10-47	1928-1929	.	_

11-1	1930-1933	All	_
11-2	1934-1936	of	_
11-3	1937-1940	the	_
11-4	1941-1953	participants	_
11-5	1954-1957	and	_
11-6	1958-1963	their	_
11-7	1964-1976	first-degree	_
11-8	1977-1986	relatives	_
11-9	1987-1990	had	_
11-10	1991-1993	no	_
11-11	1994-2001	history	_
11-12	2002-2004	of	_
11-13	2005-2016	psychiatric	_
11-14	2017-2024	disease	_
11-15	2025-2026	.	_

12-1	2027-2030	The	_
12-2	2031-2036	study	_
12-3	2037-2040	was	_
12-4	2041-2049	approved	_
12-5	2050-2052	by	_
12-6	2053-2056	the	_
12-7	2057-2062	local	_
12-8	2063-2070	Medical	_
12-9	2071-2079	Research	_
12-10	2080-2086	Ethics	_
12-11	2087-2096	Committee	_
12-12	2097-2099	of	_
12-13	2100-2107	Tianjin	_
12-14	2108-2115	Medical	_
12-15	2116-2126	University	_
12-16	2127-2128	.	_

13-1	2129-2132	All	_
13-2	2133-2145	experimental	_
13-3	2146-2153	methods	_
13-4	2154-2158	were	_
13-5	2159-2168	performed	_
13-6	2169-2171	in	_
13-7	2172-2182	accordance	_
13-8	2183-2187	with	_
13-9	2188-2191	the	_
13-10	2192-2200	relevant	_
13-11	2201-2211	guidelines	_
13-12	2212-2215	and	_
13-13	2216-2227	regulations	_
13-14	2228-2229	,	_
13-15	2230-2233	and	_
13-16	2234-2241	written	_
13-17	2242-2250	informed	_
13-18	2251-2259	consents	_
13-19	2260-2264	were	_
13-20	2265-2273	obtained	_
13-21	2274-2278	from	_
13-22	2279-2283	each	_
13-23	2284-2291	subject	_
13-24	2292-2293	.	_

14-1	2294-2300	N-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
14-2	2301-2308	working	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
14-3	2309-2315	memory	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
14-4	2316-2321	tasks	_
14-5	2322-2326	were	_
14-6	2327-2331	used	_
14-7	2332-2334	to	_
14-8	2335-2341	assess	_
14-9	2342-2349	working	_
14-10	2350-2356	memory	_
14-11	2357-2363	before	_
14-12	2364-2367	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-13	2368-2379	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-14	2380-2381	.	_

15-1	2382-2385	The	_
15-2	2386-2392	letter	_
15-3	2393-2399	2-back	_
15-4	2400-2403	and	_
15-5	2404-2410	3-back	_
15-6	2411-2416	tasks	_
15-7	2417-2421	were	_
15-8	2422-2431	described	_
15-9	2432-2442	previously	_
15-10	2443-2444	.	_

16-1	2445-2452	Briefly	_
16-2	2453-2461	speaking	_
16-3	2462-2463	,	_
16-4	2464-2465	a	_
16-5	2466-2472	series	_
16-6	2473-2475	of	_
16-7	2476-2483	letters	_
16-8	2484-2488	were	_
16-9	2489-2501	sequentially	_
16-10	2502-2511	presented	_
16-11	2512-2514	on	_
16-12	2515-2518	the	_
16-13	2519-2525	screen	_
16-14	2526-2527	,	_
16-15	2528-2532	each	_
16-16	2533-2540	subject	_
16-17	2541-2544	was	_
16-18	2545-2550	asked	_
16-19	2551-2553	to	_
16-20	2554-2558	view	_
16-21	2559-2562	and	_
16-22	2563-2568	judge	_
16-23	2569-2576	whether	_
16-24	2577-2580	the	_
16-25	2581-2587	letter	_
16-26	2588-2590	of	_
16-27	2591-2594	the	_
16-28	2595-2602	current	_
16-29	2603-2609	screen	_
16-30	2610-2613	was	_
16-31	2614-2623	identical	_
16-32	2624-2626	to	_
16-33	2627-2630	the	_
16-34	2631-2634	one	_
16-35	2635-2644	displayed	_
16-36	2645-2648	two	_
16-37	2649-2655	trials	_
16-38	2656-2657	(	_
16-39	2658-2664	2-back	_
16-40	2665-2666	)	_
16-41	2667-2670	and	_
16-42	2671-2676	three	_
16-43	2677-2683	trials	_
16-44	2684-2685	(	_
16-45	2686-2692	3-back	_
16-46	2693-2694	)	_
16-47	2695-2699	back	_
16-48	2700-2701	.	_

17-1	2702-2705	The	_
17-2	2706-2712	N-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
17-3	2713-2717	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
17-4	2718-2727	contained	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
17-5	2728-2733	three	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
17-6	2734-2740	blocks	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
17-7	2741-2742	(	_
17-8	2743-2745	30	_
17-9	2746-2752	trials	_
17-10	2753-2757	each	_
17-11	2758-2763	block	_
17-12	2764-2765	)	_
17-13	2766-2767	.	_

18-1	2768-2774	Before	_
18-2	2775-2778	the	_
18-3	2779-2785	formal	_
18-4	2786-2791	tasks	_
18-5	2792-2793	,	_
18-6	2794-2806	participants	_
18-7	2807-2811	were	_
18-8	2812-2822	instructed	_
18-9	2823-2826	and	_
18-10	2827-2831	took	_
18-11	2832-2833	a	_
18-12	2834-2842	practice	_
18-13	2843-2844	.	_

19-1	2845-2848	The	_
19-2	2849-2856	numbers	_
19-3	2857-2859	of	_
19-4	2860-2867	correct	_
19-5	2868-2871	and	_
19-6	2872-2877	false	_
19-7	2878-2887	responses	_
19-8	2888-2892	were	_
19-9	2893-2901	recorded	_
19-10	2902-2904	to	_
19-11	2905-2912	compute	_
19-12	2913-2916	the	_
19-13	2917-2925	accuracy	_
19-14	2926-2928	as	_
19-15	2929-2932	the	_
19-16	2933-2938	index	_
19-17	2939-2941	of	_
19-18	2942-2949	working	_
19-19	2950-2956	memory	_
19-20	2957-2958	.	_

20-1	2959-2964	Eight	_
20-2	2965-2973	subjects	_
20-3	2974-2978	were	_
20-4	2979-2988	discarded	_
20-5	2989-2993	from	_
20-6	2994-3001	further	_
20-7	3002-3010	analysis	_
20-8	3011-3014	due	_
20-9	3015-3017	to	_
20-10	3018-3025	missing	_
20-11	3026-3034	genotype	_
20-12	3035-3039	data	_
20-13	3040-3041	(	_
20-14	3042-3045	see	_
20-15	3046-3051	Table	_
20-16	3052-3053	1	_
20-17	3054-3057	for	_
20-18	3058-3069	demographic	_
20-19	3070-3085	characteristics	_
20-20	3086-3087	)	_
20-21	3088-3089	.	_

21-1	3090-3093	DNA	_
21-2	3094-3104	extraction	_
21-3	3105-3108	and	_
21-4	3109-3119	genotyping	_
21-5	3120-3123	DNA	_
21-6	3124-3127	was	_
21-7	3128-3137	extracted	_
21-8	3138-3142	from	_
21-9	3143-3149	venous	_
21-10	3150-3155	whole	_
21-11	3156-3161	blood	_
21-12	3162-3169	samples	_
21-13	3170-3177	treated	_
21-14	3178-3182	with	_
21-15	3183-3191	ethylene	_
21-16	3192-3199	diamine	_
21-17	3200-3215	tetraaceticacid	_
21-18	3216-3217	(	_
21-19	3218-3222	EDTA	_
21-20	3223-3224	)	_
21-21	3225-3227	as	_
21-22	3228-3230	an	_
21-23	3231-3244	anticoagulant	_
21-24	3245-3247	by	_
21-25	3248-3253	using	_
21-26	3254-3257	the	_
21-27	3258-3264	EZgene	_
21-28	3265-3270	Blood	_
21-29	3271-3283	gDNAMiniprep	_
21-30	3284-3287	Kit	_
21-31	3288-3289	(	_
21-32	3290-3297	BioMiga	_
21-33	3298-3299	,	_
21-34	3300-3303	San	_
21-35	3304-3309	Diego	_
21-36	3310-3311	,	_
21-37	3312-3314	CA	_
21-38	3315-3316	)	_
21-39	3317-3318	.	_

22-1	3319-3329	Genotyping	_
22-2	3330-3334	used	_
22-3	3335-3338	the	_
22-4	3339-3347	standard	_
22-5	3348-3356	Illumina	_
22-6	3357-3367	genotyping	_
22-7	3368-3376	protocol	_
22-8	3377-3378	(	_
22-9	3379-3387	Illumina	_
22-10	3388-3389	)	_
22-11	3390-3392	on	_
22-12	3393-3401	Illumina	_
22-13	3402-3407	Human	_
22-14	3408-3422	OmniZhongHua-8	_
22-15	3423-3427	Bead	_
22-16	3428-3433	Chips	_
22-17	3434-3435	.	_

23-1	3436-3439	The	_
23-2	3440-3449	following	_
23-3	3450-3457	quality	_
23-4	3458-3465	control	_
23-5	3466-3476	procedures	_
23-6	3477-3481	were	_
23-7	3482-3489	carried	_
23-8	3490-3493	out	_
23-9	3494-3499	using	_
23-10	3500-3505	PLINK	_
23-11	3506-3513	version	_
23-12	3514-3518	1.07	_
23-13	3519-3520	.	_

24-1	3521-3524	The	_
24-2	3525-3529	SNPs	_
24-3	3530-3534	were	_
24-4	3535-3542	removed	_
24-5	3543-3548	where	_
24-6	3549-3552	the	_
24-7	3553-3557	call	_
24-8	3558-3562	rate	_
24-9	3563-3566	was	_
24-10	3567-3568	<	_
24-11	3569-3571	95	_
24-12	3572-3573	%	_
24-13	3574-3575	,	_
24-14	3576-3578	if	_
24-15	3579-3582	the	_
24-16	3583-3588	minor	_
24-17	3589-3595	allele	_
24-18	3596-3605	frequency	_
24-19	3606-3609	was	_
24-20	3610-3611	<	_
24-21	3612-3613	1	_
24-22	3614-3615	%	_
24-23	3616-3617	,	_
24-24	3618-3620	or	_
24-25	3621-3623	if	_
24-26	3624-3627	the	_
24-27	3628-3630	χ2	_
24-28	3631-3635	test	_
24-29	3636-3638	of	_
24-30	3639-3653	Hardy-Weinberg	_
24-31	3654-3665	equilibrium	_
24-32	3666-3669	was	_
24-33	3670-3671	<	_
24-34	3672-3676	10−3	_
24-35	3677-3678	.	_

25-1	3679-3681	In	_
25-2	3682-3690	addition	_
25-3	3691-3692	,	_
25-4	3693-3704	individuals	_
25-5	3705-3709	were	_
25-6	3710-3717	removed	_
25-7	3718-3722	from	_
25-8	3723-3726	the	_
25-9	3727-3732	study	_
25-10	3733-3735	if	_
25-11	3736-3741	their	_
25-12	3742-3749	missing	_
25-13	3750-3758	genotype	_
25-14	3759-3764	rates	_
25-15	3765-3769	were	_
25-16	3770-3771	>	_
25-17	3772-3773	5	_
25-18	3774-3775	%	_
25-19	3776-3777	,	_
25-20	3778-3780	if	_
25-21	3781-3784	the	_
25-22	3785-3793	estimate	_
25-23	3794-3796	of	_
25-24	3797-3805	pairwise	_
25-25	3806-3825	identity-by-descent	_
25-26	3826-3827	(	_
25-27	3828-3831	IBD	_
25-28	3832-3833	)	_
25-29	3834-3837	was	_
25-30	3838-3839	>	_
25-31	3840-3846	0.1875	_
25-32	3847-3848	,	_
25-33	3849-3851	or	_
25-34	3852-3854	if	_
25-35	3855-3858	the	_
25-36	3859-3865	gender	_
25-37	3866-3876	identified	_
25-38	3877-3879	by	_
25-39	3880-3881	X	_
25-40	3882-3892	chromosome	_
25-41	3893-3900	markers	_
25-42	3901-3909	differed	_
25-43	3910-3914	from	_
25-44	3915-3918	the	_
25-45	3919-3926	patient	_
25-46	3927-3934	records	_
25-47	3935-3936	.	_

26-1	3937-3939	To	_
26-2	3940-3947	control	_
26-3	3948-3951	for	_
26-4	3952-3962	population	_
26-5	3963-3977	stratification	_
26-6	3978-3979	,	_
26-7	3980-3982	we	_
26-8	3983-3994	ascertained	_
26-9	3995-4005	population	_
26-10	4006-4015	structure	_
26-11	4016-4021	using	_
26-12	4022-4031	principal	_
26-13	4032-4041	component	_
26-14	4042-4050	analyses	_
26-15	4051-4052	(	_
26-16	4053-4056	PCA	_
26-17	4057-4058	)	_
26-18	4059-4061	in	_
26-19	4062-4072	EIGENSTRAT	_
26-20	4073-4081	software	_
26-21	4082-4083	(	_
26-22	4084-4088	http	_
26-23	4089-4090	:	_
26-24	4091-4148	//www.hsph.harvard.edu/alkes-price/files/eigensoftfaq.htm	_
26-25	4149-4150	)	_
26-26	4151-4153	on	_
26-27	4154-4163	autosomal	_
26-28	4164-4168	SNPs	_
26-29	4169-4173	with	_
26-30	4174-4177	the	_
26-31	4178-4184	HapMap	_
26-32	4185-4190	phase	_
26-33	4191-4192	3	_
26-34	4193-4202	reference	_
26-35	4203-4207	data	_
26-36	4208-4211	set	_
26-37	4212-4213	.	_

27-1	4214-4219	Prior	_
27-2	4220-4222	to	_
27-3	4223-4226	the	_
27-4	4227-4230	PCA	_
27-5	4231-4232	,	_
27-6	4233-4235	we	_
27-7	4236-4243	removed	_
27-8	4244-4255	chromosomal	_
27-9	4256-4263	regions	_
27-10	4264-4266	of	_
27-11	4267-4277	long-range	_
27-12	4278-4285	linkage	_
27-13	4286-4300	disequilibrium	_
27-14	4301-4302	(	_
27-15	4303-4305	LD	_
27-16	4306-4307	)	_
27-17	4308-4311	and	_
27-18	4312-4320	retained	_
27-19	4321-4325	SNPs	_
27-20	4326-4330	that	_
27-21	4331-4335	were	_
27-22	4336-4338	in	_
27-23	4339-4342	low	_
27-24	4343-4345	LD	_
27-25	4346-4350	with	_
27-26	4351-4355	each	_
27-27	4356-4361	other	_
27-28	4362-4363	.	_

28-1	4364-4369	After	_
28-2	4370-4380	extracting	_
28-3	4381-4383	10	_
28-4	4384-4393	principal	_
28-5	4394-4404	components	_
28-6	4405-4406	,	_
28-7	4407-4409	we	_
28-8	4410-4417	removed	_
28-9	4418-4421	the	_
28-10	4422-4429	samples	_
28-11	4430-4437	outside	_
28-12	4438-4439	6	_
28-13	4440-4448	standard	_
28-14	4449-4459	deviations	_
28-15	4460-4461	.	_

29-1	4462-4465	The	_
29-2	4466-4470	data	_
29-3	4471-4475	were	_
29-4	4476-4480	then	_
29-5	4481-4488	imputed	_
29-6	4489-4494	using	_
29-7	4495-4504	SHAPEITv2	_
29-8	4505-4506	(	_
29-9	4507-4512	https	_
29-10	4513-4514	:	_
29-11	4515-4578	//mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html	_
29-12	4579-4580	)	_
29-13	4581-4584	and	_
29-14	4585-4592	IMPUTE2	_
29-15	4593-4594	(	_
29-16	4595-4600	https	_
29-17	4601-4602	:	_
29-18	4603-4649	//mathgen.stats.ox.ac.uk/impute/impute_v2.html	_
29-19	4650-4651	)	_
29-20	4652-4656	with	_
29-21	4657-4660	the	_
29-22	4661-4665	1000	_
29-23	4666-4673	Genomes	_
29-24	4674-4679	Phase	_
29-25	4680-4681	1	_
29-26	4682-4691	reference	_
29-27	4692-4699	dataset	_
29-28	4700-4701	.	_

30-1	4702-4709	Further	_
30-2	4710-4718	analyses	_
30-3	4719-4726	focused	_
30-4	4727-4729	on	_
30-5	4730-4733	315	_
30-6	4734-4742	subjects	_
30-7	4743-4747	with	_
30-8	4748-4752	more	_
30-9	4753-4757	than	_
30-10	4758-4759	7	_
30-11	4760-4767	million	_
30-12	4768-4777	autosomal	_
30-13	4778-4782	SNPs	_
30-14	4783-4784	,	_
30-15	4785-4790	whose	_
30-16	4791-4801	imputation	_
30-17	4802-4809	quality	_
30-18	4810-4816	scores	_
30-19	4817-4821	were	_
30-20	4822-4829	greater	_
30-21	4830-4834	than	_
30-22	4835-4838	0.8	_
30-23	4839-4840	.	_

31-1	4841-4852	Computation	_
31-2	4853-4855	of	_
31-3	4856-4864	dopamine	_
31-4	4865-4878	genes-related	_
31-5	4879-4883	PGRS	_
31-6	4884-4886	We	_
31-7	4887-4891	used	_
31-8	4892-4895	the	_
31-9	4896-4897	“	_
31-10	4898-4903	score	_
31-11	4904-4905	”	_
31-12	4906-4914	function	_
31-13	4915-4926	implemented	_
31-14	4927-4929	in	_
31-15	4930-4935	PLINK	_
31-16	4936-4938	to	_
31-17	4939-4946	compute	_
31-18	4947-4950	the	_
31-19	4951-4959	dopamine	_
31-20	4960-4973	genes-related	_
31-21	4974-4983	polygenic	_
31-22	4984-5002	schizophrenia-risk	_
31-23	5003-5008	score	_
31-24	5009-5010	.	_

32-1	5011-5014	The	_
32-2	5015-5019	PGRS	_
32-3	5020-5023	was	_
32-4	5024-5034	calculated	_
32-5	5035-5044	according	_
32-6	5045-5047	to	_
32-7	5048-5051	the	_
32-8	5052-5058	method	_
32-9	5059-5068	developed	_
32-10	5069-5071	by	_
32-11	5072-5079	Purcell	_
32-12	5080-5082	et	_
32-13	5083-5085	al	_
32-14	5086-5088	..	_
32-15	5089-5092	Our	_
32-16	5093-5101	analyses	_
32-17	5102-5109	focused	_
32-18	5110-5112	on	_
32-19	5113-5118	those	_
32-20	5119-5124	genes	_
32-21	5125-5133	involved	_
32-22	5134-5136	in	_
32-23	5137-5145	dopamine	_
32-24	5146-5157	functioning	_
32-25	5158-5159	:	_
32-26	5160-5161	(	_
32-27	5162-5163	i	_
32-28	5164-5165	)	_
32-29	5166-5175	synthesis	_
32-30	5176-5177	(	_
32-31	5178-5186	tyrosine	_
32-32	5187-5198	hydroxylase	_
32-33	5199-5200	(	_
32-34	5201-5203	TH	_
32-35	5204-5205	)	_
32-36	5206-5207	,	_
32-37	5208-5212	dopa	_
32-38	5213-5226	decarboxylase	_
32-39	5227-5228	(	_
32-40	5229-5232	DDC	_
32-41	5233-5234	)	_
32-42	5235-5236	,	_
32-43	5237-5240	and	_
32-44	5241-5250	vesicular	_
32-45	5251-5260	monoamine	_
32-46	5261-5272	transporter	_
32-47	5273-5274	(	_
32-48	5275-5279	VMAT	_
32-49	5280-5281	)	_
32-50	5282-5283	)	_
32-51	5284-5285	;	_
32-52	5286-5287	(	_
32-53	5288-5290	ii	_
32-54	5291-5292	)	_
32-55	5293-5299	uptake	_
32-56	5300-5303	and	_
32-57	5304-5314	metabolism	_
32-58	5315-5316	(	_
32-59	5317-5325	dopamine	_
32-60	5326-5337	transporter	_
32-61	5338-5339	(	_
32-62	5340-5343	DAT	_
32-63	5344-5345	)	_
32-64	5346-5349	and	_
32-65	5350-5367	catechol-O-methyl	_
32-66	5368-5379	transferase	_
32-67	5380-5381	(	_
32-68	5382-5386	COMT	_
32-69	5387-5388	)	_
32-70	5389-5390	)	_
32-71	5391-5392	;	_
32-72	5393-5394	(	_
32-73	5395-5398	iii	_
32-74	5399-5400	)	_
32-75	5401-5410	receptors	_
32-76	5411-5412	(	_
32-77	5413-5415	D1	_
32-78	5416-5419	and	_
32-79	5420-5422	D5	_
32-80	5423-5432	receptors	_
32-81	5433-5435	in	_
32-82	5436-5438	D1	_
32-83	5439-5445	family	_
32-84	5446-5447	,	_
32-85	5448-5450	as	_
32-86	5451-5455	well	_
32-87	5456-5458	as	_
32-88	5459-5461	D2	_
32-89	5462-5463	,	_
32-90	5464-5466	D3	_
32-91	5467-5470	and	_
32-92	5471-5473	D4	_
32-93	5474-5476	in	_
32-94	5477-5479	D2	_
32-95	5480-5486	family	_
32-96	5487-5488	)	_
32-97	5489-5490	.	_

33-1	5491-5493	We	_
33-2	5494-5503	evaluated	_
33-3	5504-5507	all	_
33-4	5508-5517	available	_
33-5	5518-5522	SNPs	_
33-6	5523-5527	both	_
33-7	5528-5537	occurring	_
33-8	5538-5540	in	_
33-9	5541-5544	the	_
33-10	5545-5549	area	_
33-11	5550-5554	5000	_
33-12	5555-5557	bp	_
33-13	5558-5566	upstream	_
33-14	5567-5570	and	_
33-15	5571-5581	downstream	_
33-16	5582-5584	of	_
33-17	5585-5589	each	_
33-18	5590-5599	candidate	_
33-19	5600-5604	gene	_
33-20	5605-5608	and	_
33-21	5609-5616	meeting	_
33-22	5617-5618	a	_
33-23	5619-5631	significance	_
33-24	5632-5637	level	_
33-25	5638-5640	of	_
33-26	5641-5642	p	_
33-27	5643-5644	≤	_
33-28	5645-5649	0.05	_
33-29	5650-5652	in	_
33-30	5653-5656	the	_
33-31	5657-5668	multi-stage	_
33-32	5669-5682	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
33-33	5683-5687	GWAS	_
33-34	5688-5693	study	_
33-35	5694-5701	because	_
33-36	5702-5706	this	_
33-37	5707-5710	was	_
33-38	5711-5714	the	_
33-39	5715-5720	level	_
33-40	5721-5725	that	_
33-41	5726-5730	most	_
33-42	5731-5742	efficiently	_
33-43	5743-5756	discriminated	_
33-44	5757-5768	individuals	_
33-45	5769-5773	with	_
33-46	5774-5777	and	_
33-47	5778-5785	without	_
33-48	5786-5799	schizophrenia	_
33-49	5800-5801	.	_

34-1	5802-5805	The	_
34-2	5806-5810	SNPs	_
34-3	5811-5815	were	_
34-4	5816-5822	pruned	_
34-5	5823-5828	using	_
34-6	5829-5832	the	_
34-7	5833-5834	“	_
34-8	5835-5840	clump	_
34-9	5841-5842	”	_
34-10	5843-5850	utility	_
34-11	5851-5853	in	_
34-12	5854-5859	PLINK	_
34-13	5860-5864	with	_
34-14	5865-5866	a	_
34-15	5867-5873	cutoff	_
34-16	5874-5876	of	_
34-17	5877-5879	r2	_
34-18	5880-5881	=	_
34-19	5882-5886	0.50	_
34-20	5887-5893	within	_
34-21	5894-5895	a	_
34-22	5896-5899	250	_
34-23	5900-5902	kb	_
34-24	5903-5909	window	_
34-25	5910-5912	to	_
34-26	5913-5919	ensure	_
34-27	5920-5924	that	_
34-28	5925-5928	the	_
34-29	5929-5938	polygenic	_
34-30	5939-5946	effects	_
34-31	5947-5951	come	_
34-32	5952-5956	from	_
34-33	5957-5968	independent	_
34-34	5969-5973	SNPs	_
34-35	5974-5976	in	_
34-36	5977-5984	linkage	_
34-37	5985-5999	disequilibrium	_
34-38	6000-6004	with	_
34-39	6005-6009	each	_
34-40	6010-6015	other	_
34-41	6016-6017	(	_
34-42	6018-6031	Supplementary	_
34-43	6032-6037	table	_
34-44	6038-6039	1	_
34-45	6040-6046	showed	_
34-46	6047-6050	the	_
34-47	6051-6055	SNPs	_
34-48	6056-6059	and	_
34-49	6060-6067	weights	_
34-50	6068-6072	used	_
34-51	6073-6075	to	_
34-52	6076-6084	generate	_
34-53	6085-6088	the	_
34-54	6089-6093	PGRS	_
34-55	6094-6095	)	_
34-56	6096-6097	.	_

35-1	6098-6103	Image	_
35-2	6104-6115	acquisition	_
35-3	6116-6119	and	_
35-4	6120-6130	processing	_
35-5	6131-6137	Images	_
35-6	6138-6142	were	_
35-7	6143-6152	collected	_
35-8	6153-6158	using	_
35-9	6159-6160	a	_
35-10	6161-6167	single	_
35-11	6168-6170	3T	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
35-12	6171-6173	GE	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
35-13	6174-6181	scanner	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
35-14	6182-6183	(	_
35-15	6184-6195	SIGNAHDX3.0	_
35-16	6196-6197	T	_
35-17	6198-6205	scanner	_
35-18	6206-6207	;	_
35-19	6208-6210	GE	_
35-20	6211-6221	Healthcare	_
35-21	6222-6223	;	_
35-22	6224-6233	Milwaukee	_
35-23	6234-6235	,	_
35-24	6236-6238	WI	_
35-25	6239-6240	,	_
35-26	6241-6244	USA	_
35-27	6245-6246	)	_
35-28	6247-6248	.	_

36-1	6249-6250	A	_
36-2	6251-6262	single-shot	_
36-3	6263-6264	,	_
36-4	6265-6267	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
36-5	6268-6269	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
36-6	6270-6279	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
36-7	6280-6288	gradient	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
36-8	6289-6293	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
36-9	6294-6295	,	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
36-10	6296-6315	echo-planar-imaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
36-11	6316-6324	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
36-12	6325-6326	(	_
36-13	6327-6329	TR	_
36-14	6330-6331	=	_
36-15	6332-6336	2000	_
36-16	6337-6339	ms	_
36-17	6340-6341	,	_
36-18	6342-6344	TE	_
36-19	6345-6346	=	_
36-20	6347-6349	30	_
36-21	6350-6352	ms	_
36-22	6353-6354	,	_
36-23	6355-6357	no	_
36-24	6358-6361	gap	_
36-25	6362-6363	,	_
36-26	6364-6369	voxel	_
36-27	6370-6374	size	_
36-28	6375-6376	=	_
36-29	6377-6381	3.75	_
36-30	6382-6384	mm	_
36-31	6385-6386	×	_
36-32	6387-6391	3.75	_
36-33	6392-6394	mm	_
36-34	6395-6396	×	_
36-35	6397-6400	4.0	_
36-36	6401-6403	mm	_
36-37	6404-6405	,	_
36-38	6406-6409	FOV	_
36-39	6410-6411	=	_
36-40	6412-6415	240	_
36-41	6416-6417	×	_
36-42	6418-6421	240	_
36-43	6422-6425	mm2	_
36-44	6426-6427	,	_
36-45	6428-6434	matrix	_
36-46	6435-6436	=	_
36-47	6437-6439	64	_
36-48	6440-6441	×	_
36-49	6442-6444	64	_
36-50	6445-6446	,	_
36-51	6447-6451	flip	_
36-52	6452-6457	angle	_
36-53	6458-6459	=	_
36-54	6460-6463	90°	_
36-55	6464-6465	,	_
36-56	6466-6468	40	_
36-57	6469-6475	slices	_
36-58	6476-6477	,	_
36-59	6478-6481	180	_
36-60	6482-6489	volumes	_
36-61	6490-6491	)	_
36-62	6492-6495	was	_
36-63	6496-6500	used	_
36-64	6501-6503	to	_
36-65	6504-6510	obtain	_
36-66	6511-6524	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-67	6525-6535	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-68	6536-6544	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-69	6545-6554	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-70	6555-6562	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-71	6563-6567	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-72	6568-6569	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-73	6570-6574	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-74	6575-6576	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-75	6577-6578	.	_

37-1	6579-6582	All	_
37-2	6583-6591	subjects	_
37-3	6592-6596	were	_
37-4	6597-6606	requested	_
37-5	6607-6609	to	_
37-6	6610-6615	relax	_
37-7	6616-6619	and	_
37-8	6620-6622	to	_
37-9	6623-6626	not	_
37-10	6627-6631	fall	_
37-11	6632-6638	asleep	_
37-12	6639-6640	.	_

38-1	6641-6644	Two	_
38-2	6645-6656	experienced	_
38-3	6657-6669	radiologists	_
38-4	6670-6679	inspected	_
38-5	6680-6683	all	_
38-6	6684-6687	the	_
38-7	6688-6691	raw	_
38-8	6692-6695	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-9	6696-6700	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-10	6701-6702	.	_

39-1	6703-6716	Preprocessing	_
39-2	6717-6719	of	_
39-3	6720-6730	functional	_
39-4	6731-6737	images	_
39-5	6738-6741	was	_
39-6	6742-6751	performed	_
39-7	6752-6757	using	_
39-8	6758-6765	DPARSFA	_
39-9	6766-6767	(	_
39-10	6768-6772	Data	_
39-11	6773-6783	Processing	_
39-12	6784-6793	Assistant	_
39-13	6794-6797	for	_
39-14	6798-6811	Resting-State	_
39-15	6812-6816	fMRI	_
39-16	6817-6825	Advanced	_
39-17	6826-6833	Edition	_
39-18	6834-6835	,	_
39-19	6836-6840	http	_
39-20	6841-6842	:	_
39-21	6843-6874	//www.restfmri.net/forum/DPARSF	_
39-22	6875-6876	)	_
39-23	6877-6879	in	_
39-24	6880-6891	statistical	_
39-25	6892-6902	parametric	_
39-26	6903-6910	mapping	_
39-27	6911-6919	software	_
39-28	6920-6921	(	_
39-29	6922-6926	SPM8	_
39-30	6927-6928	,	_
39-31	6929-6933	http	_
39-32	6934-6935	:	_
39-33	6936-6963	//www.fil.ion.ucl.ac.uk/spm	_
39-34	6964-6965	)	_
39-35	6966-6967	.	_

40-1	6968-6971	The	_
40-2	6972-6985	preprocessing	_
40-3	6986-6994	included	_
40-4	6995-7005	discarding	_
40-5	7006-7009	the	_
40-6	7010-7015	first	_
40-7	7016-7018	10	_
40-8	7019-7026	volumes	_
40-9	7027-7028	,	_
40-10	7029-7034	slice	_
40-11	7035-7041	timing	_
40-12	7042-7043	,	_
40-13	7044-7048	head	_
40-14	7049-7055	motion	_
40-15	7056-7066	correction	_
40-16	7067-7068	,	_
40-17	7069-7078	spatially	_
40-18	7079-7090	normalizing	_
40-19	7091-7093	to	_
40-20	7094-7097	the	_
40-21	7098-7106	Montreal	_
40-22	7107-7119	Neurological	_
40-23	7120-7129	Institute	_
40-24	7130-7131	(	_
40-25	7132-7135	MNI	_
40-26	7136-7137	)	_
40-27	7138-7146	template	_
40-28	7147-7148	,	_
40-29	7149-7159	resampling	_
40-30	7160-7162	to	_
40-31	7163-7164	3	_
40-32	7165-7166	×	_
40-33	7167-7168	3	_
40-34	7169-7170	×	_
40-35	7171-7172	3	_
40-36	7173-7176	mm3	_
40-37	7177-7178	,	_
40-38	7179-7188	smoothing	_
40-39	7189-7193	with	_
40-40	7194-7195	a	_
40-41	7196-7197	6	_
40-42	7198-7200	mm	_
40-43	7201-7209	Gaussian	_
40-44	7210-7216	kernel	_
40-45	7217-7218	,	_
40-46	7219-7227	temporal	_
40-47	7228-7237	band-pass	_
40-48	7238-7247	filtering	_
40-49	7248-7249	,	_
40-50	7250-7253	and	_
40-51	7254-7260	linear	_
40-52	7261-7271	regression	_
40-53	7272-7274	to	_
40-54	7275-7281	remove	_
40-55	7282-7285	the	_
40-56	7286-7295	influence	_
40-57	7296-7298	of	_
40-58	7299-7307	nuisance	_
40-59	7308-7315	signals	_
40-60	7316-7325	including	_
40-61	7326-7330	head	_
40-62	7331-7337	motion	_
40-63	7338-7348	parameters	_
40-64	7349-7352	and	_
40-65	7353-7358	white	_
40-66	7359-7365	matter	_
40-67	7366-7367	,	_
40-68	7368-7381	cerebrospinal	_
40-69	7382-7387	fluid	_
40-70	7388-7391	and	_
40-71	7392-7398	global	_
40-72	7399-7406	signals	_
40-73	7407-7408	.	_

41-1	7409-7413	Then	_
41-2	7414-7415	,	_
41-3	7416-7418	we	_
41-4	7419-7428	discarded	_
41-5	7429-7431	14	_
41-6	7432-7444	participants	_
41-7	7445-7450	whose	_
41-8	7451-7458	maximum	_
41-9	7459-7471	displacement	_
41-10	7472-7474	in	_
41-11	7475-7478	any	_
41-12	7479-7481	of	_
41-13	7482-7485	the	_
41-14	7486-7494	cardinal	_
41-15	7495-7505	directions	_
41-16	7506-7507	(	_
41-17	7508-7509	x	_
41-18	7510-7511	,	_
41-19	7512-7513	y	_
41-20	7514-7515	,	_
41-21	7516-7517	z	_
41-22	7518-7519	)	_
41-23	7520-7523	was	_
41-24	7524-7531	greater	_
41-25	7532-7536	than	_
41-26	7537-7538	2	_
41-27	7539-7541	mm	_
41-28	7542-7544	or	_
41-29	7545-7550	whose	_
41-30	7551-7558	maximum	_
41-31	7559-7563	spin	_
41-32	7564-7565	(	_
41-33	7566-7567	x	_
41-34	7568-7569	,	_
41-35	7570-7571	y	_
41-36	7572-7573	,	_
41-37	7574-7575	z	_
41-38	7576-7577	)	_
41-39	7578-7581	was	_
41-40	7582-7589	greater	_
41-41	7590-7594	than	_
41-42	7595-7597	2°	_
41-43	7598-7599	.	_

42-1	7600-7602	In	_
42-2	7603-7606	the	_
42-3	7607-7610	end	_
42-4	7611-7612	,	_
42-5	7613-7616	286	_
42-6	7617-7625	subjects	_
42-7	7626-7634	remained	_
42-8	7635-7637	in	_
42-9	7638-7641	the	_
42-10	7642-7652	functional	_
42-11	7653-7665	connectivity	_
42-12	7666-7674	analysis	_
42-13	7675-7676	.	_

43-1	7677-7680	The	_
43-2	7681-7685	seed	_
43-3	7686-7693	regions	_
43-4	7694-7695	(	_
43-5	7696-7705	bilateral	_
43-6	7706-7713	caudate	_
43-7	7714-7721	nucleus	_
43-8	7722-7723	,	_
43-9	7724-7731	putamen	_
43-10	7732-7735	and	_
43-11	7736-7743	ventral	_
43-12	7744-7752	striatum	_
43-13	7753-7754	)	_
43-14	7755-7759	were	_
43-15	7760-7769	extracted	_
43-16	7770-7775	based	_
43-17	7776-7778	on	_
43-18	7779-7782	the	_
43-19	7783-7801	Oxford-GSK-Imanova	_
43-20	7802-7823	Structural-anatomical	_
43-21	7824-7832	Striatal	_
43-22	7833-7838	Atlas	_
43-23	7839-7840	,	_
43-24	7841-7844	and	_
43-25	7845-7848	the	_
43-26	7849-7854	masks	_
43-27	7855-7858	for	_
43-28	7859-7862	the	_
43-29	7863-7867	seed	_
43-30	7868-7875	regions	_
43-31	7876-7880	were	_
43-32	7881-7890	resampled	_
43-33	7891-7893	to	_
43-34	7894-7895	3	_
43-35	7896-7897	×	_
43-36	7898-7899	3	_
43-37	7900-7901	×	_
43-38	7902-7903	3	_
43-39	7904-7907	mm3	_
43-40	7908-7910	in	_
43-41	7911-7914	MNI	_
43-42	7915-7920	space	_
43-43	7921-7922	.	_

44-1	7923-7925	We	_
44-2	7926-7936	calculated	_
44-3	7937-7940	the	_
44-4	7941-7948	Pearson	_
44-5	7949-7950	’	_
44-6	7951-7952	s	_
44-7	7953-7964	correlation	_
44-8	7965-7976	coefficient	_
44-9	7977-7984	between	_
44-10	7985-7988	the	_
44-11	7989-7996	average	_
44-12	7997-8001	time	_
44-13	8002-8008	series	_
44-14	8009-8011	of	_
44-15	8012-8015	the	_
44-16	8016-8020	seed	_
44-17	8021-8028	regions	_
44-18	8029-8032	and	_
44-19	8033-8038	those	_
44-20	8039-8041	of	_
44-21	8042-8045	all	_
44-22	8046-8049	the	_
44-23	8050-8056	voxels	_
44-24	8057-8059	of	_
44-25	8060-8063	the	_
44-26	8064-8069	whole	_
44-27	8070-8075	brain	_
44-28	8076-8077	.	_

45-1	8078-8082	Then	_
45-2	8083-8084	,	_
45-3	8085-8087	we	_
45-4	8088-8099	transformed	_
45-5	8100-8103	the	_
45-6	8104-8105	r	_
45-7	8106-8117	correlation	_
45-8	8118-8122	into	_
45-9	8123-8124	a	_
45-10	8125-8126	Z	_
45-11	8127-8132	score	_
45-12	8133-8136	via	_
45-13	8137-8143	Fisher	_
45-14	8144-8145	’	_
45-15	8146-8147	s	_
45-16	8148-8154	r-to-z	_
45-17	8155-8169	transformation	_
45-18	8170-8172	in	_
45-19	8173-8178	order	_
45-20	8179-8181	to	_
45-21	8182-8188	obtain	_
45-22	8189-8190	Z	_
45-23	8191-8195	maps	_
45-24	8196-8199	for	_
45-25	8200-8204	each	_
45-26	8205-8212	subject	_
45-27	8213-8214	.	_

46-1	8215-8219	Next	_
46-2	8220-8221	,	_
46-3	8222-8232	one-sample	_
46-4	8233-8240	t-tests	_
46-5	8241-8245	were	_
46-6	8246-8250	used	_
46-7	8251-8253	to	_
46-8	8254-8263	determine	_
46-9	8264-8267	the	_
46-10	8268-8272	main	_
46-11	8273-8283	functional	_
46-12	8284-8298	connectivities	_
46-13	8299-8301	in	_
46-14	8302-8305	for	_
46-15	8306-8310	each	_
46-16	8311-8319	striatal	_
46-17	8320-8330	sub-region	_
46-18	8331-8332	.	_

47-1	8333-8337	Then	_
47-2	8338-8339	,	_
47-3	8340-8342	we	_
47-4	8343-8347	used	_
47-5	8348-8351	the	_
47-6	8352-8357	masks	_
47-7	8358-8360	of	_
47-8	8361-8364	the	_
47-9	8365-8375	one-sample	_
47-10	8376-8383	t-tests	_
47-11	8384-8391	results	_
47-12	8392-8395	for	_
47-13	8396-8406	subsequent	_
47-14	8407-8415	multiple	_
47-15	8416-8426	regression	_
47-16	8427-8435	analysis	_
47-17	8436-8437	.	_

48-1	8438-8449	Statistical	_
48-2	8450-8458	analysis	_
48-3	8459-8469	Voxel-wise	_
48-4	8470-8478	multiple	_
48-5	8479-8489	regression	_
48-6	8490-8498	analysis	_
48-7	8499-8502	was	_
48-8	8503-8514	implemented	_
48-9	8515-8517	in	_
48-10	8518-8522	SPM8	_
48-11	8523-8525	to	_
48-12	8526-8537	investigate	_
48-13	8538-8541	the	_
48-14	8542-8553	correlation	_
48-15	8554-8561	between	_
48-16	8562-8570	dopamine	_
48-17	8571-8583	gene-related	_
48-18	8584-8588	PGRS	_
48-19	8589-8592	and	_
48-20	8593-8596	the	_
48-21	8597-8607	seed-based	_
48-22	8608-8618	functional	_
48-23	8619-8631	connectivity	_
48-24	8632-8633	.	_

49-1	8634-8636	To	_
49-2	8637-8644	correct	_
49-3	8645-8648	for	_
49-4	8649-8657	multiple	_
49-5	8658-8669	statistical	_
49-6	8670-8677	testing	_
49-7	8678-8679	,	_
49-8	8680-8682	we	_
49-9	8683-8693	maintained	_
49-10	8694-8695	a	_
49-11	8696-8709	cluster-level	_
49-12	8710-8724	false-positive	_
49-13	8725-8734	detection	_
49-14	8735-8739	rate	_
49-15	8740-8742	at	_
49-16	8743-8744	p	_
49-17	8745-8746	<	_
49-18	8747-8751	0.05	_
49-19	8752-8757	using	_
49-20	8758-8759	a	_
49-21	8760-8771	voxel-level	_
49-22	8772-8781	threshold	_
49-23	8782-8784	of	_
49-24	8785-8786	p	_
49-25	8787-8788	<	_
49-26	8789-8794	0.001	_
49-27	8795-8796	(	_
49-28	8797-8810	Supplementary	_
49-29	8811-8818	Figures	_
49-30	8819-8821	S1	_
49-31	8822-8825	and	_
49-32	8826-8828	S2	_
49-33	8829-8830	)	_
49-34	8831-8834	and	_
49-35	8835-8836	a	_
49-36	8837-8848	voxel-level	_
49-37	8849-8858	threshold	_
49-38	8859-8861	of	_
49-39	8862-8863	p	_
49-40	8864-8865	<	_
49-41	8866-8871	0.005	_
49-42	8872-8876	with	_
49-43	8877-8878	a	_
49-44	8879-8886	cluster	_
49-45	8887-8893	extent	_
49-46	8894-8904	determined	_
49-47	8905-8907	by	_
49-48	8908-8913	Monte	_
49-49	8914-8919	Carlo	_
49-50	8920-8931	simulations	_
49-51	8932-8933	(	_
49-52	8934-8935	n	_
49-53	8936-8937	=	_
49-54	8938-8942	5000	_
49-55	8943-8953	iterations	_
49-56	8954-8955	)	_
49-57	8956-8957	.	_

50-1	8958-8960	We	_
50-2	8961-8973	accomplished	_
50-3	8974-8978	this	_
50-4	8979-8983	step	_
50-5	8984-8989	using	_
50-6	8990-8998	Alphasim	_
50-7	8999-9010	implemented	_
50-8	9011-9013	in	_
50-9	9014-9017	the	_
50-10	9018-9022	Data	_
50-11	9023-9033	Processing	_
50-12	9034-9035	&	_
50-13	9036-9044	Analysis	_
50-14	9045-9048	for	_
50-15	9049-9054	Brain	_
50-16	9055-9062	Imaging	_
50-17	9063-9067	V2.3	_
50-18	9068-9069	(	_
50-19	9070-9075	DPABI	_
50-20	9076-9077	,	_
50-21	9078-9082	http	_
50-22	9083-9084	:	_
50-23	9085-9102	//rfmri.org/dpabi	_
50-24	9103-9104	)	_
50-25	9105-9106	.	_

51-1	9107-9109	To	_
51-2	9110-9119	determine	_
51-3	9120-9123	the	_
51-4	9124-9134	functional	_
51-5	9135-9143	networks	_
51-6	9144-9146	to	_
51-7	9147-9152	which	_
51-8	9153-9158	brain	_
51-9	9159-9166	regions	_
51-10	9167-9171	with	_
51-11	9172-9183	significant	_
51-12	9184-9195	correlation	_
51-13	9196-9200	with	_
51-14	9201-9204	the	_
51-15	9205-9209	PGRS	_
51-16	9210-9218	belonged	_
51-17	9219-9220	,	_
51-18	9221-9223	we	_
51-19	9224-9233	performed	_
51-20	9234-9239	group	_
51-21	9240-9251	independent	_
51-22	9252-9261	component	_
51-23	9262-9270	analysis	_
51-24	9271-9272	(	_
51-25	9273-9278	group	_
51-26	9279-9282	ICA	_
51-27	9283-9284	)	_
51-28	9285-9287	to	_
51-29	9288-9296	separate	_
51-30	9297-9300	the	_
51-31	9301-9306	blood	_
51-32	9307-9313	oxygen	_
51-33	9314-9329	level-dependent	_
51-34	9330-9336	signal	_
51-35	9337-9341	into	_
51-36	9342-9353	independent	_
51-37	9354-9364	components	_
51-38	9365-9370	using	_
51-39	9371-9381	theprogram	_
51-40	9382-9387	Group	_
51-41	9388-9391	ICA	_
51-42	9392-9394	of	_
51-43	9395-9399	fMRI	_
51-44	9400-9407	Toolbox	_
51-45	9408-9409	(	_
51-46	9410-9414	GIFT	_
51-47	9415-9416	)	_
51-48	9417-9418	(	_
51-49	9419-9423	http	_
51-50	9424-9425	:	_
51-51	9426-9450	//icatb.sourceforge.net/	_
51-52	9451-9452	)	_
51-53	9453-9454	.	_

52-1	9455-9460	Based	_
52-2	9461-9463	on	_
52-3	9464-9465	a	_
52-4	9466-9474	previous	_
52-5	9475-9480	study	_
52-6	9481-9483	by	_
52-7	9484-9489	Simth	_
52-8	9490-9492	et	_
52-9	9493-9496	al.	_
52-10	9497-9498	,	_
52-11	9499-9501	we	_
52-12	9502-9512	identified	_
52-13	9513-9517	nine	_
52-14	9518-9531	resting-state	_
52-15	9532-9540	networks	_
52-16	9541-9542	,	_
52-17	9543-9552	including	_
52-18	9553-9556	the	_
52-19	9557-9564	default	_
52-20	9565-9569	mode	_
52-21	9570-9577	network	_
52-22	9578-9581	and	_
52-23	9582-9585	the	_
52-24	9586-9601	fronto-parietal	_
52-25	9602-9609	network	_
52-26	9610-9611	,	_
52-27	9612-9615	and	_
52-28	9616-9618	we	_
52-29	9619-9627	obtained	_
52-30	9628-9631	the	_
52-31	9632-9636	mean	_
52-32	9637-9646	component	_
52-33	9647-9652	masks	_
52-34	9653-9654	.	_

53-1	9655-9657	In	_
53-2	9658-9666	addition	_
53-3	9667-9668	,	_
53-4	9669-9676	partial	_
53-5	9677-9688	correlation	_
53-6	9689-9697	analysis	_
53-7	9698-9701	was	_
53-8	9702-9711	performed	_
53-9	9712-9714	to	_
53-10	9715-9719	test	_
53-11	9720-9723	the	_
53-12	9724-9735	correlation	_
53-13	9736-9743	between	_
53-14	9744-9747	the	_
53-15	9748-9752	PGRS	_
53-16	9753-9756	and	_
53-17	9757-9764	working	_
53-18	9765-9771	memory	_
53-19	9772-9783	performance	_
53-20	9784-9786	as	_
53-21	9787-9791	well	_
53-22	9792-9794	as	_
53-23	9795-9805	functional	_
53-24	9806-9818	connectivity	_
53-25	9819-9823	with	_
53-26	9824-9832	striatal	_
53-27	9833-9844	sub-regions	_
53-28	9845-9849	with	_
53-29	9850-9853	age	_
53-30	9854-9855	,	_
53-31	9856-9862	gender	_
53-32	9863-9866	and	_
53-33	9867-9870	the	_
53-34	9871-9876	first	_
53-35	9877-9882	three	_
53-36	9883-9890	genetic	_
53-37	9891-9900	principal	_
53-38	9901-9911	components	_
53-39	9912-9914	as	_
53-40	9915-9925	covariates	_
53-41	9926-9927	.	_

54-1	9928-9930	We	_
54-2	9931-9938	further	_
54-3	9939-9942	did	_
54-4	9943-9951	post-hoc	_
54-5	9952-9957	tests	_
54-6	9958-9960	to	_
54-7	9961-9970	determine	_
54-8	9971-9976	which	_
54-9	9977-9981	SNPs	_
54-10	9982-9987	might	_
54-11	9988-9990	be	_
54-12	9991-9994	the	_
54-13	9995-9999	most	_
54-14	10000-10011	responsible	_
54-15	10012-10015	for	_
54-16	10016-10019	the	_
54-17	10020-10028	observed	_
54-18	10029-10035	effect	_
54-19	10036-10041	using	_
54-20	10042-10047	PLINK	_
54-21	10048-10055	version	_
54-22	10056-10060	1.07	_
54-23	10061-10062	.	_

55-1	10063-10067	Data	_
55-2	10068-10080	availability	_
55-3	10081-10084	The	_
55-4	10085-10093	datasets	_
55-5	10094-10102	analyzed	_
55-6	10103-10109	during	_
55-7	10110-10113	the	_
55-8	10114-10121	current	_
55-9	10122-10127	study	_
55-10	10128-10131	are	_
55-11	10132-10141	available	_
55-12	10142-10146	from	_
55-13	10147-10150	the	_
55-14	10151-10164	corresponding	_
55-15	10165-10171	author	_
55-16	10172-10174	on	_
55-17	10175-10185	reasonable	_
55-18	10186-10193	request	_
55-19	10194-10195	.	_

